Met Life Investment Management, LLC Arcutis Biotherapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 61,658 shares of ARQT stock, worth $816,351. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61,658
Previous 61,658
-0.0%
Holding current value
$816,351
Previous $573,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding ARQT
# of Institutions
196Shares Held
130MCall Options Held
738KPut Options Held
82K-
Jennison Associates LLC12.3MShares$163 Million0.11% of portfolio
-
Rubric Capital Management LP New York, NY11MShares$145 Million2.84% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.7MShares$142 Million3.92% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$116 Million4.4% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$114 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $797M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...